Generic drugmakers are hesitant to get into the follow-on biologics market because of legal challenges, as well as the complexity and cost of developing copies of biotech drugs that are approaching patent expiration, analysts say. "It's really a market for bigger companies which can make the investment to explore," said a manager for a health care fund for ING Investment Management.

Full Story:

Related Summaries